tbuckley/cabot-search huggingface dataset:
Abstract 14808: Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy
Authors: Ziad Hijazi, Jonas Oldgren, Ulrika Andersson, Stuart J Connolly, Michael D Ezekowitz, Stefan H Hohnloser, Paul A Reilly, Agneta Siegbahn, Salim Yusuf, Lars Wallentin
Journal: Circulation (2012)

Background: Cardiac troponin I (cTnI) and N-terminal-B-type natriuretic peptide (NT-proBNP) predict poor prognosis in atrial fibrillation (AF) patients. However, it is not known whether transient o...
Infographic. Sleep disorders in athletes
Authors: Claudia L Reardon, Brian Hainline, Cindy Miller Aron, David Baron, Antonia L Baum, Abhinav Bindra, Richard Budgett, Niccolo Campriani, João Mauricio Castaldelli-Maia, Alan Currie, Jeffrey Lee Derevensky, Ira D Glick, Paul Gorczynski, Vincent Gouttebarge, Michael A Grandner, Doug Hyun Han, David McDuff, Margo Mountjoy, Aslihan Polat, Rosemary Purcell, Margot Putukian, Simon M Rice, Allen Sills, Todd Stull, Leslie Swartz, Li Jing Zhu, Lars Engebretsen
Journal: British Journal of Sports Medicine (2019)

![Figure][1]</img> 1. 1. 2. Reardon CL , 3. Hainline B , 4. Aron CM , et al . Mental health in elite athletes: international Olympic Committee consensus statement (2019). Br J Sports Med 2019;53:667–99.[doi:10.1136/bjsports-2019-100715][2] [OpenUrl][3][
AB1276 THE RISK OF DIABETES MELLITUS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: A COHORT STUDY
Authors: Hemin Lee, Yinzhu Jin, Jun Liu, Ezra Cohen, Sarah Chen, Seoyoung Kim
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Few studies have suggested higher prevalence of type 1 diabetes mellitus (DM) in juvenile idiopathic arthritis (JIA). To date, the risk of type 1 or 2 DM among patients with JIA patients has not been fully understood. <h3>Objectives</h3> To examine the incidence rate (IR) of DM in JIA patients compared to patients with asthma and healthy children. <h3>Methods</h3> We conducted a cohort study using a U.S. claims data from Truven MarketScan (2005-2016). We identified individuals between age 6 and 18 with ≥2 diagnoses of JIA with International Classification of Diseases (ICD)-9 and 10 diagnostic codes followed by one dispensing of JIA-treatment medication. For comparison, we selected 1) children with asthma and 2) healthy individuals. Each JIA patient was matched by age, sex and index date to 5 asthma patients and 5 healthy children. The primary outcome was DM, identified with 1 ICD diagnostic code followed by one dispensing of an antidiabetic drug. We assessed type 1 DM and type 2 DM separately, and composite endpoint of type 1 or 2 DM. IR and hazard ratio (HR) of DM in JIA patients versus patients with asthma and healthy subjects was calculated along with stratification by age (6 to 12 versus 13 to 18). <h3>Results</h3> After 1:5 matching, there were 74,385 healthy children, 74,385 asthma patients, and 14,877 JIA patients. The mean age in all cohorts was 13.9 years and 66.9% were female. During a mean follow up of 3.72 years, the composite IR of DM in the JIA group was 0.85 per 1,000 person-years (95% Confidence Interval [CI], 0.61-1.19) compared to 0.63 (0.54-0.74) per 1,000 person-years in the asthma population and 0.53 (0.45-0.62) per 1,000 person-years in the healthy population (Table 1). The multivariable adjusted HR (95% CI) associated with DM in JIA was 1.27 (0.77-2.07) compared to the asthma group and 1.47 (0.90-2.42) compared to the healthy population (Table 2). Age-stratified analyses also showed numerically increased risk of DM in JIA patients. † The study cohorts were age-, sex-, and index date-matched. IR is per 1,000 person-years <h3>Conclusion</h3> In our cohort of 163,647 children with 14,877 JIA patients, JIA was associated with a numerically higher, albeit not statistically significant, risk of type 1 or 2 DM compared to asthma patients or healthy children. <h3>References</h3> [1] Schenck S, et al. Comorbidity of Type 1 Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis. The Journal of pediatrics. Jan 2018;192:196-203. <h3>Acknowledgement</h3> This study was supported by an investigator-initiated research grant from Bristol-Myer-Squibb. <h3>Disclosure of Interests</h3> Hemin Lee: None declared, Yinzhu Jin: None declared, Jun Liu: None declared, Ezra Cohen: None declared, Sarah Chen: None declared, Seoyoung Kim Grant/research support from: Pfizer, Bristol-Myers Squibb, Roche/Genentech and AbbVie.
Increasing tolerance of hospital <i>Enterococcus faecium</i> to handwash alcohols
Authors: Sacha J. Pidot, Wei Gao, Andrew H. Buultjens, Ian R. Monk, Romain Guerillot, Glen P. Carter, Jean Y. H. Lee, Margaret M. C. Lam, M. Lindsay Grayson, Susan A. Ballard, Andrew A. Mahony, Elizabeth A. Grabsch, Despina Kotsanas, Tony M. Korman, Geoffrey W. Coombs, J. Owen Robinson, Anders Gonçalves da Silva, Torsten Seemann, Benjamin P. Howden, Paul D. R. Johnson, Timothy P. Stinear
Journal: Science Translational Medicine (2018)

The multidrug-resistant bacterium Enterococcus faecium has become increasingly tolerant to the alcohols in hospital disinfectants.
OP0273 HPR FUNCTIONAL EXERCISE FOR ADULTS WITH CHRONIC NON-SPECIFIC LOW BACK PAIN: A RANDOMIZED CONTROLLED TRIAL
Authors: Emilia Moreira, Anamaria Jones, Eider Da Silva Lima, Fabio Jennings, Jamil Natour
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Exercise therapy is part of the recommendation for the treatment of chronic non-specific low back pain (LBP). Functional exercise may be an alternative for the treatment, no studies assessing its effectiveness were found. <h3>Objectives</h3> To assess the effectiveness of the functional exercise program for pain, functional capacity, general health, kinesiophobia and perceived exertion in adults with chronic nonspecific LBP. <h3>Methods</h3> A randomized controlled clinical trial with intention-to-treat analysis and 24-week follow-up was performed. Eighty-four patients were randomly assigned to an experimental group (EG) or control group (CG). The EG participated in the functional exercises program performed twice a week for twelve weeks. The functional exercise program was composed by global exercise that worked the group of muscles of the trunk and lower and upper limbs with progression every 4 weeks. The two groups received an informative class on the disease and were advised to use analgesic if necessary. Primary outcome was LBP measured by numeric rating scale (NRS). Secondary outcomes included was functional capacity by Oswestry and Roland Morris questionnaires, 6-minute walk and TUG tests, kinesiophobia (FABQ), general health (SF-36), perceived exertion (BORG). Evaluations were performed at baseline, after 6, 12 (end of intervention) and 24 weeks by a blind evaluator. <h3>Results</h3> The groups were homogeneous for all parameters at baseline. Compared with the CG, the EG statistically improved pain, functional capacity, kinesiophobia, some domains of general health and peceived exertion - Table 1. <h3>Conclusion</h3> The functional exercise program was effective to improve pain, functional capacity, kinesiophobia, general health and percepived exertion in adults with chronic nonspecific LBP. <h3>References</h3> [1] Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. Arthritis and Rheumatism. 2012. [2] Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, et al. What low back pain is and why we need to pay attention. The Lancet. 2018. <h3>Disclosure of Interests</h3> None declared
PB2340 INCIDENCE AND SEVERITY OF ORAL MUCOSITIS AMONG ALLOGENEIC STEM CELL TRANSPLANTATION PATIENTS FOLLOWING FOUR TYPES CONDITIONING REGIMENS
Authors: S. Torihata, M. Sukedai, T. Shimoide, H. Ehara, H. Kanazawa, M. Yasumoto, N. Yasutake, A. Shimoide, A. Enomoto, S. Hamada, T. Ashida
Journal: HemaSphere (2019)

Background: Oral mucositis (OM) is a painful and debilitating complication of allogeneic hematopoietic stem cell transplantation (HSCT). Conditioning regimen correlates development of OM, but no studies have analyzed incidence and severity of OM among various condition regimens. Aims: This study was designed to evaluate the incidence and severity of OM receiving various conditioning regimens in early period after HSCT. Methods: We included 120 adult patients with a median age of 54.5 years (range 18 ‐ 72) who received allogeneic HSCT at Kindai University Hospital. Four conditioning regimens were administered for patients before transplantation based on the underlying diseases. Twenty‐two patients were received cyclophosphamide (CY)/total body irradiation (TBI) regimen (CY/TBI), 27 were received busulfan (BU)/CY regimen (BU/CY), 54 were received fludarabine (FLU)/BU regimen (FLU/BU), and 17 were received FLU/ melphalan (MEL) regimen (FLU/MEL). National Cancer Institute Common Toxicity Criteria for Adverse Events scale was used to assess the severity of OM. Severe OM defined as grade 2 to 4. Results: OM of any grades occurred 77.3% of CY/TBI, 48.1% of BU/CY, 85.2% of FLU/BU, and 70.6% of FLU/MEL. There were significant differences between CY/TBI and BU/CY (p = 0.05), and BU/CY and FLU/BU (p = 0.001). There was no patient with grade 4 OM. The incidence of severe OM (grade 2 ‐ 3) was 54.5% of CY/TBI, 18.5% of BU/CY, 57.4% of FLU/BU, and 52.9% of FLU/MEL. There were significant differences between CY/TBI and BU/CY (p = 0.02), BU/CY and FLU/BU (p = 0.0009), and BU/CY and FLU/MEL (p = 0.02). Summary/Conclusion: Incidence and severity of OM in patients receiving BU/CY regimen was the lowest among 4 types conditioning regimens.
Abstract MP089: Sleep Apnea is Reduced Following a Behavioral Weight Loss Intervention but Impedes Weight Loss Outcomes
Authors: Christopher E Kline, Lora E Burke, Susan M Sereika, Christopher C Imes, Lynn M Baniak, Dara D Mendez, Patrick J Strollo, Lei Ye, Eileen R Chasens
Journal: Circulation (2017)

Introduction: Several trials have documented that behavioral weight loss interventions reduce obstructive sleep apnea (OSA) severity. However, despite the known bidirectional association between body weight and OSA severity, few studies have addressed whether the presence of OSA impedes weight loss outcomes in a lifestyle intervention. Hypothesis: We hypothesized that a behavioral weight loss intervention would significantly reduce OSA severity, but that the presence of OSA would lead to poorer weight loss outcomes. Methods: Overweight and obese adults (N = 101; 50.6 ± 10.3 y, body mass index: 34.1 ± 4.6; 91.1% female, 80.2% white) who participated in a 12-mo behavioral weight loss intervention study and had OSA assessed were included in these secondary analyses. Participants wore a limited-channel home sleep testing device (ResMed ApneaLink Plus) for one night at baseline, 6 and 12 mo. Measures of OSA severity included the apnea-hypopnea index (AHI), oxygen desaturation index (ODI), and snoring index (i.e., number of snoring events divided by flow recording time). Weight change at 6 and 12 mo was expressed as percentage change from baseline. Linear mixed models were used to evaluate the effect of the intervention on OSA measures, and ANCOVA models examined the effect of weight change on OSA and the effect of OSA on subsequent weight loss. All analyses were adjusted for age, sex, and race. Results: Baseline AHI, ODI, and snoring index were 6.6 ± 7.1, 8.7 ± 8.3, and 109.9 ± 122.0, respectively; 50.5% of the sample had a baseline AHI ≥ 5. AHI and ODI, but not the snoring index, were significantly reduced by the end of the intervention (12-mo changes: -1.3 [P &lt; .05], -2.3 [P &lt; .01], -2.8 [P = .82], respectively). Weight loss at 6 and 12 mo were 9.0 ± 6.0% and 9.1 ± 8.3%, respectively. Participants with ≥ 5% weight loss at 6 mo had significant reductions in AHI (P = .02), ODI (P &lt; .05), and the snoring index (P &lt; .001) at 6 mo; adults with ≥ 5% weight loss at 12 mo had a significant reduction in the snoring index at 12 mo (P &lt; .01), but not AHI (P = .29) or ODI (P = .39), relative to baseline. Participants with a baseline AHI ≥ 5 lost significantly less weight at 6 mo compared to those without OSA at baseline (-8.4% vs. -11.4%; P &lt; .01), and those with an AHI ≥ 5 at 6 mo lost significantly less weight at 12 mo compared to those without OSA at 6 mo (-7.1% vs. -10.9%; P = .04). Conclusion: Behavioral weight loss interventions in overweight and obese adults lead to significant improvement in OSA severity. However, the presence of at least mild OSA is associated with less favorable weight loss in this population. Future work should explore the mechanisms underlying the blunted weight loss in overweight and obese adults with OSA.
PF796 THE EFFECT OF ANTI‐BETA2‐GLYCOPROTEIN I ANTIBODY UPON THROMBIN GENERATION IN NORMAL, LEIDEN HETEROZYGOUS AND FACTOR DEFICIENT PLASMAS
Authors: G. Szabó, T. Tarr, P. Soltész, J. Kappelmayer
Journal: HemaSphere (2019)

Background: The antiphospholipid syndrome (APS) is an acquired hypercoagulable condition, in which venous or arterial thromboses are caused by the presence of antiphospholipid antibodies (aPL). Anti‐β 2 glycoprotein I (anti‐β 2 GPI), highly correlating with the clinical manifestation of the syndrome, is the most significant aPL. Much evidence has uncovered insights into its molecular mechanisms, the exact molecular or cellular events are still not delineated. Aims: Our aim was to examine the effect of anti‐β 2 GPI antibodies from APS patients on pooled normal plasma (NP), Leiden heterozygous plasma (LP) and factor deficient plasmas (DP). Methods: Serum samples were collected form triple positive (anti‐β 2 GPI, anticardiolipin, lupus anticoagulant) APS patients with thrombosis in their history. Anti‐β 2 GPI IgG was purified in a two‐step affinity chromatography by Protein G and β 2 GPI affinity columns. Purified anti‐β 2 GPI IgG was added to NP, LP, or DP in thrombin generation test (TGT) up to 125 U/mL concentration in the presence of 1 pM tissue factor and 4 μM phospholipid. Results: In TGT, time (Lag Time) and quantity parameters (Peak and Endogenous Thrombin Potential [ETP]) were assessed. Having lupus anticoagulant effect, anti‐β 2 GPI showed significant prolongation in Lag Time in pooled NP (n = 9) by 24% ( p &lt; 0.001). Despite the fact that anti‐β 2 GPI delayed thrombin generation in time, it significantly increased ETP by 11% ( p &lt; 0.001). We assessed thrombin generation in LP samples without antibodies. Thrombin generation in LP began at the same time as that of the NP, there was no difference in Lag Time, but surprisingly Peak and ETP values were significantly lower than in NP (ETP NP : 1467 nM ∗ min, ETP LP : 920 nM ∗ min, p &lt; 0.001), less thrombin was generated in LP. Anti‐β 2 GPI was able to exert similar effects on LP as in NP. Lag Time was delayed by 36% ( p &lt; 0.001), there was a non‐significant increase in ETP, but the Peak thrombin value was elevated by 32% ( p &lt; 0.05, n = 6). The effect of anti‐β 2 GPI was investigated on FVII, FIX, FXI and FXII deficient plasmas. Similar tendency was seen in intrinsic factor deficient plasmas, Lag Time was prolonged, Peak and ETP was elevated, but anti‐β 2 GPI could not exert significant effect on any of the deficient plasmas. However, the lack of FVII completely prevented the effect of anti‐β 2 GPI on thrombin generation. Summary/Conclusion: Anti‐β 2 GPI delayed thrombin generation in time, while it enhanced the amount of thrombin generated, which may in part explain the lupus anticoagulant paradox. In plasma from Leiden heterozygous patients, thrombin generation was also enhanced by anti‐β 2 GPI. In intrinsic factor (FIX, FXI, FXII) deficient plasmas, similar tendency was seen as in normal or Leiden plasmas, which was non‐significant, but FVII seems a crucial mediator in the prothrombotic effect of anti‐β 2 GPI antibodies.
PS1057 INDUCTION WITH FLUGA SCHEME AND MAINTENANCE WITH DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OF 65 YEARS AND OLDER
Authors: S.B. Costa, M. Marín Gimenez, M. Uribe Barrientos, P.R. Pedro, F. Ibañez Alís, M. Roig Pellicer, M.T. Orero Castelló, L.P. María, M.J. Lis Chulvi, F. Hernández Muñoz, A. Mena Durán, R. Collado Nieto, A. Cerveró Martí, M. Linares García
Journal: HemaSphere (2019)

Background: Chromosome 17 (ch17) abnormalities, especially loss of the 17p region and P53 gene mutations (p53mut) result in very low rates of cure for patients with acute myeloid leukemia (AML) treated with conventional chemotherapy or allogenic stem cell transplant (ASCT). Aims: We assessed whether such poor outcomes extend to patients with all types of ch17 abnormalities and whether p53mut has further prognostic value. Methods: We retrospectively analyzed 98 patients at our institution with AML/myelodysplastic syndrome (MDS) who had ch17 abnormalities noted on cytogenetics. p53mut was analyzed by next generation sequencing (NGS). Results: 61 patients with AML and 37 patients with MDS were included. Patient characteristics are in Table 1. 95 out of the 98 patients had 17p abnormalities as part of a complex karyotype, whereas 67 out of the 98 patients had a monosomal karyotype. Complete remission (CR) with first line treatment was similar between induction chemotherapy or hypomethylating agents, 22.9% vs 21.6 % (p = 0.33). Median overall survival (OS) for all patients was 10 months. Ch17 abnormalities were classified into those resulting in deletion of the p53 loci such as 17p deletion and monosomy 17 (17pdel/mono17) and all other ch17 abnormalities (ch17oth). Amongst patients with 17pdel/mono17with NGS available, 19 of 26 had p53mut, while for ch17oth, 13 of 17 had p53mut (p = 0.72).Patients having both p53mut and abnormal ch17 exhibited poorer OS compared to patients with no p53mut (10 vs 23 months, p = 0.02). 30 patients (19 AML, 11 MDS) underwent ASCT, with a median post-transplant OS of 11 months. For AML ASCT patients, 18 were in CR (13 with cytogenetic remission) and 1 had refractory disease at transplant, whereas for MDS patients, 3 were in CR (2 with cytogenetic remission) and 8 had stable disease. The post-ASCT survival between AML/MDS cohorts did not differ (p = 0.6), although cytogenetic CR at time of ASCT trended towards improved OS (17 vs 8 months; p = 0.6). At last follow-up, only 5 of 30 patients were alive, 4 in CR.Summary/Conclusion: AML/MDS patients with all types of ch17 abnormalities have a poor prognosis with or without ASCT, representing a distinct subset of patients amongst that that have complex cytogenetics. TP53 abnormalities detected by NGS are not limited to patients with 17pdel/mono17 and can be seen with other ch17 abnormalities. Drugs targeting the TP53 pathway and improving depth of response prior to ASCT are needed for improved outcomes in these patients.
After an acute coronary syndrome, alirocumab reduced total nonfatal CV events and deaths vs placebo
Authors: Eric R. Bates
Journal: Annals of Internal Medicine (2019)

Source Citation Szarek M, White HD, Schwartz GG, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;73:387-96. 30428396
Assessment of Underage Sales Violations in Tobacco Stores and Vape Shops
Authors: April Roeseler, Tam D. Vuong, Lisa Henriksen, Xueying Zhang
Journal: JAMA Pediatrics (2019)

This study assesses whether the US Food and Drug Administration regulation to limit the sale of flavored tobacco products to age-restricted locations is adequate based on a 1-year review of violations rates in age-restricted shops.
Abstract 18233: Ca2+/Calmodulin-Dependent Protein Kinases II Phosphorylation of Ryanodine Receptor 2 Contributes to the Development of Chronic Atrial Fibrillation
Authors: Na Li, Tiannan Wang, Wei Wang, Frank U Müller, Xander H Wehrens
Journal: Circulation (2010)

Introduction: Cardiac ryanodine receptor (RyR2) mediated abnormal Ca2+ release has been implicated in the initiation and maintenance of atrial fibrillation (AF). We previously demonstrated that Ca2...
SP0172 CASE 2 PRESENTER: ALWAYS AT THE EDGE: SEVERE GI COMPLICATIONS
Authors: Kristina Clark
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> The clinical impact of lower gastrointestinal tract involvement in systemic sclerosis will be illustrated through a case presentation. This will describe the challenges of managing patients with systemic sclerosis presenting with pseudo-obstruction, severe malnutrition, and electrolyte imbalance and how these were managed to optimise patient care. <h3>Disclosure of Interests:</h3> None declared
Abstract 19383: Impact of Tight Glycemic Control on the Neurodevelopmental Outcomes at One Year of Age of Children with Congenital Heart Disease
Authors: Anjali Sadhwani, Lisa Asaro, Caren Goldberg, Janice Ware, Jennifer Butcher, David Wypij, Michael Gaies, Cynthia Smith, Jamin Alexander, Michael Agus
Journal: Circulation (2014)

Background: While postoperative tight glycemic control (TGC) may reduce morbidity in certain subgroups of children undergoing cardiac surgery, its association with later neurodevelopmental outcomes...
PB1992 HEMATOPOIETIC LIKE CELLS DERIVED FROM CANCER STEM CELLS GENERATED FROM MOUSE INDUCED PLURIPOTENT STEM CELLS: NOVEL CONCEPT FOR CANCER ASSOCIATED HEMATOPOIESIS
Authors: G. Hassan, S.M. Afify, K. Kumon, M. Zahra, N. Okada, A. Seno, M. Seno
Journal: HemaSphere (2019)

Background: Cancer stem cells (CSCs) represent the subpopulation of cancer cells with plasticity to differentiate into other cell phenotypes. Previously, we reported to generate cancer stem cells from mouse induced pluripotent stem cells with the potential to develop endothelial cells and cancer associated fibroblasts of angiogenesis. In the other hand, recent reports showed that erythrocytes could be derived from the tumor. However, the ability of CSCs to exhibit different hematopoietic cells is still unclear. Aims: To investigate the hematopoiesis phenomena from CSCs in vitro. Methods: Viability of non‐adherent cells (NACs) arising from cancer stem cells (expressing GFP under Nanog promoter) was analyzed by flow cytometry using Annexin V and PI. The morphology and expression of CD34 and LIN markers were also investigated using Giemsa staining, flow cytometry, and immunofluorescence staining, respectively. Molecular phenotype of NACs was examined by RT‐PCR. Clonogenic assay was conducted by culturing NACs on mouse embryonic fibroblast (MEF). Results: The round nucleated cells with heterogeneous diameter were observed on the surface of cancer stem cells adhered on the bottom of dish. Approximately 80% of NACs were found viable according to Annexin V and PI staining while 60% were positive for Lin markers and 0.35% were positive for CD34. NACs were found to express hematopoietic marker genes for CD34, CD38, CD10, c‐Kit and EPO‐R by RT‐PCR as well as to form colonies on MEF. Summary/Conclusion: CSCs were demonstrated to have potential to provide progenies with hematopoietic marker and morphology as cancer associated hematopoietic cells, which could give a new insight of tumor microenvironment according to the plasticity of cancer stem cells.
Abstract 11005: Pre-Procedural Neutrophil to Lymphocyte Ratio on Long-Term Clinical Outcomes in Coronary Artery Disease Patients With Low High-Sensitivity C-Reactive Protein Level
Authors: Hideki Wada, Tomotaka Dohi, Katsumi Miyauchi, Mitsuhiro Takeuchi, Norihito Takahashi, Hirohisa Endo, Manabu Ogita, Satoru Suwa, Hiroyuki Daida
Journal: Circulation (2018)

Introduction: The pre-procedural neutrophil to lymphocyte (NLR) has been associated with adverse outcomes among coronary artery disease (CAD). Less in known, however, about its prognostic value amo...
Abstract 15586: The Role of B-type Natriuretic Peptide in Diagnosing Acute Decompensated Heart Failure in Chronic Kidney Disease Patients
Authors: Amer Kadri, Roop Kaw, Yasser Al-Khadra, Hasan Abuamsha, Keyvan Ravakhah, Adrian Hernandez-Diaz, W. H. Wilson Tang
Journal: Circulation (2017)

Introduction: Patients with chronic kidney disease (CKD) and CHF have higher serum BNP levels, which alter the test interpretation Hypothesis: We are proposing new BNP cutoff levels to diagnose acu...